Nobuyuki Yamamoto

Sign up to set email alerts
|
25Publications
9,488Citation Statements Received
561Citation Statements Given
How they've been cited
11,419
408
9,007
73
How they cite others
750
38
519
4
Publications
Order By: Most citations

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Sequist
1
,
Yang
2
,
Yamamoto
3
et al. 2013
JCO
2,804
92
2,124
19
View full textAdd to dashboardCite
show abstract

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang
1
,
Wu
2
,
Schüler3
et al. 2015
The Lancet Oncology
1,384
50
1,027
5
View full textAdd to dashboardCite

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

Yang
1
,
Sequist
2
,
Geater
3
et al. 2015
The Lancet Oncology
786
42
716
4
View full textAdd to dashboardCite

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Hida
1
,
Nokihara2,
Kondo
3
et al. 2017
The Lancet
752
16
618
3
View full textAdd to dashboardCite

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Seto
1
,
Kato
2
,
Nishio
3
et al. 2014
The Lancet Oncology
660
18
570
3
2
View full textAdd to dashboardCite

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Nakagawa1,
Garon2,
Seto3
et al. 2019
The Lancet Oncology
427
20
399
2
View full textAdd to dashboardCite

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

Seto
1
,
Kiura
2
,
Nishio
3
et al. 2013
The Lancet Oncology
522
11
406
3
View full textAdd to dashboardCite

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

Takahashi
1
,
Yamanaka
2
,
Seto
3
et al. 2017
The Lancet Oncology
413
2
390
1
View full textAdd to dashboardCite
scite logo

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Product
Browser ExtensionAssistant by sciteCitation Statement SearchReference CheckVisualizationsDashboardsExplore JournalsExplore OrganizationsExplore FundersEmbedding BadgeEmbedding Citation SearchPricing
Resources
BlogHelp & FAQAccessibility StatementAPI TermsFor Universities & GovernmentsFor ResearchersFor PublishersFor Corporate, Pharma & EnterpriseAuthor MarketingBecome an AffiliateGet an organization trial or quotescite Data & Services
About
News & PressCareersRead our PaperCoverage

BlogTerms and ConditionsAPI TermsPrivacy PolicyContactCookie PreferencesDo Not Sell or Share My Personal Information

Copyright © 2024 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.